Skip to main content
. Author manuscript; available in PMC: 2020 Nov 26.
Published in final edited form as: Oncogene. 2020 May 26;39(25):4798–4813. doi: 10.1038/s41388-020-1332-2

Fig. 2.

Fig. 2.

EZH2 mediates cisplatin resistance in SCLC. a H128 and c H146 cells were transfected with siRNA targeting EZH2, ATR, or a NT control. 72 hours after transfection, cells were treated with cisplatin for 72 hours prior to measuring cell viability. b and d Western blot analysis of EZH2 expression in b H128 and d H146 cells, respectively, demonstrating EZH2 knockdown. e Western blot analysis of EZH2 expression across a panel of SCLC cell lines. f Densitometry quantification of EZH2 expression corresponding to e was plotted against cisplatin IC50 [47] across a panel of SCLC cell lines, with a correlation of 0.7355. (For a and c, mean and standard deviation of three replicas is shown.) *** indicates p < 0.001.